Douglas Bell1, Kim Betts2, Robert Justo3, Nadine Forde4, Prem Venugopal5, Antonio F Corno6, Paul Smith4, Massimo Caputo7, Roberto Marsico7, Tom R Karl8, Nelson Alphonso9. 1. University of Queensland School of Medicine, University of Queensland, Brisbane, Australia. 2. Institute for Social Science Research, University of Queensland, Brisbane, Australia. 3. University of Queensland School of Medicine, University of Queensland, Brisbane, Australia; Queensland Pediatric Cardiac Research, Queensland Children's Hospital, Brisbane, Australia. 4. Queensland Health Forensic and Scientific Services, Brisbane, Australia. 5. Queensland Pediatric Cardiac Research, Queensland Children's Hospital, Brisbane, Australia. 6. East Midlands Congenital Heart Center, University Hospital of Leicester, Leicester, United Kingdom. 7. Bristol Heart Institute, Bristol Royal Hospital for Children, Bristol, United Kingdom. 8. Johns Hopkins School of Medicine, Baltimore, Maryland. 9. University of Queensland School of Medicine, University of Queensland, Brisbane, Australia; Queensland Pediatric Cardiac Research, Queensland Children's Hospital, Brisbane, Australia; School of Clinical Medicine, Children's Health Queensland Clinical Unit, University of Queensland, Brisbane, Australia. Electronic address: nelsonalphonso@mac.com.
Abstract
BACKGROUND: The purpose of this study was to assess the performance of more than 500 tissue-engineered bovine pericardial implants (CardioCel; Admedus, Toowong, Queensland, Australia) used for the repair of congenital heart defects. METHODS: Clinical data were collected for all patients who received a CardioCel implant at three centers (Brisbane, Australia; and Leicester and Bristol, United Kingdom). During this period, 501 CardioCel patches were implanted in 377 patients. The primary endpoint was CardioCel-related surgical or catheter intervention. Secondary endpoints included implant-related thromboembolism, residual shunt, infection, calcification leading to loss of function, and hemodynamic compromise. Mortality or reintervention was considered early if the event occurred within 30 days of implantation. RESULTS: The median follow-up was 31 months (range, 1 to 60). There were 11 deaths (2.9%), 1 related to CardioCel. There was no echocardiographic or radiologic evidence of patch calcification in any patient. Overall freedom from reintervention 3 and 5 years after implantation was 96% (95% confidence interval, 93% to 98%). Fourteen implants (2.8%) required 18 reinterventions (3.6%) at the site of implantation (9 catheter based and 9 operative). There was no difference in the incidence of reintervention in the pulmonary arterial or systemic circulations (P = .18). There was no difference in performance of CardioCel in neonates (aged 0 to 28 days), infants (aged 29 to 365 days), or children aged more than 1 year (P = .22). CONCLUSIONS: CardioCel has good durability when used for the repair of congenital heart defects. It performs comparably in the systemic and pulmonary circulations in neonates, infants, and older children.
BACKGROUND: The purpose of this study was to assess the performance of more than 500 tissue-engineered bovine pericardial implants (CardioCel; Admedus, Toowong, Queensland, Australia) used for the repair of congenital heart defects. METHODS: Clinical data were collected for all patients who received a CardioCel implant at three centers (Brisbane, Australia; and Leicester and Bristol, United Kingdom). During this period, 501 CardioCel patches were implanted in 377 patients. The primary endpoint was CardioCel-related surgical or catheter intervention. Secondary endpoints included implant-related thromboembolism, residual shunt, infection, calcification leading to loss of function, and hemodynamic compromise. Mortality or reintervention was considered early if the event occurred within 30 days of implantation. RESULTS: The median follow-up was 31 months (range, 1 to 60). There were 11 deaths (2.9%), 1 related to CardioCel. There was no echocardiographic or radiologic evidence of patch calcification in any patient. Overall freedom from reintervention 3 and 5 years after implantation was 96% (95% confidence interval, 93% to 98%). Fourteen implants (2.8%) required 18 reinterventions (3.6%) at the site of implantation (9 catheter based and 9 operative). There was no difference in the incidence of reintervention in the pulmonary arterial or systemic circulations (P = .18). There was no difference in performance of CardioCel in neonates (aged 0 to 28 days), infants (aged 29 to 365 days), or children aged more than 1 year (P = .22). CONCLUSIONS: CardioCel has good durability when used for the repair of congenital heart defects. It performs comparably in the systemic and pulmonary circulations in neonates, infants, and older children.
Authors: Mehmet H Kural; Yuling Li; Juan Wang; Kaleb M Naegeli; Emmanuelle A Hugentobler; Laura E Niklason Journal: Circ Res Date: 2022-06-23 Impact factor: 23.213
Authors: Jaroslav Chlupac; Roman Matejka; Miroslav Konarik; Robert Novotny; Zuzana Simunkova; Iveta Mrazova; Ondrej Fabian; Milan Zapletal; Zdenek Pulda; Jan Falk Lipensky; Jana Stepanovska; Karel Hanzalek; Antonin Broz; Tomas Novak; Alena Lodererova; Ludek Voska; Theodor Adla; Jiri Fronek; Miroslav Rozkot; Serhiy Forostyak; Peter Kneppo; Lucie Bacakova; Jan Pirk Journal: Int J Mol Sci Date: 2022-03-18 Impact factor: 5.923
Authors: Ingrid M van Beynum; Serife Kurul; Thomas Krasemann; Michiel Dalinghaus; Pieter van de Woestijne; Jonathan R Etnel; Ad J J C Bogers Journal: World J Pediatr Congenit Heart Surg Date: 2021-07